Recs

2

4 Big Takeovers That Went Very Wrong

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

This article has been adapted from Fool UK, our sister site across the pond.

Billionaire investment guru Warren Buffett once wryly remarked: "When a chief executive officer is encouraged by his advisors to make deals, he responds much as would a teenage boy who is encouraged by his father to have a normal sex life. It's not a push he needs."

The urge to merge
Of course, CEOs have big egos, and nothing boosts their self-esteem (and personal wealth) quite so much as a huge (and, ideally, transformational) deal.

While CEOs claim that it's cheaper to buy than to build, mergers and acquisitions frequently have a destructive effect. Indeed, they can easily turn two plus two into something considerably less than four.

For instance, a recent survey by KPMG showed that a third of deals boost the buyer's share price, a third do nothing to it, and a third reduce the buyer's share price. Thus, two-thirds of M&A deals spell bad news for the buyer's shareholders.

On the other hand, the latest research by consultancy Towers Watson and the Cass Business School found that publicly listed companies making big acquisitions sharply outperform their peers over the following quarter. Towers Watson found "a sustained outperformance for acquirers over the last three years of the research."

However, this may prove to be a short-term quirk, fueled by bargain-basement prices during the global financial crash.

Terrible tie-ups
I'm something of an M&A skeptic, even going so far as to make an anti-M&A speech at a London function in 2004. At this conference, I argued that these deals were good for city professionals but bad for shareholders as a whole.

In my experience, the seller's shareholders often profit at the expense of the buyer's shareholders, a situation known as "the buyer's curse." Also, M&A activity provides fat fees to investment bankers and higher remuneration for board directors, yet acquisition sprees frequently disappoint companies' owners -- their shareholders.

I favor smaller, bolt-on acquisitions to high-risk mega-mergers. Too often, operational problems undermine the rationale for doing such deals.

Here are four examples of big deals gone bad -- among Mr. Market's worst.

1. Vodafone/Mannesmann
For sheer destruction of shareholder value, Vodafone's (NYSE: VOD  ) takeover of German rival Mannesmann immediately springs to mind.

In February 2000, just before the tech bubble burst, the agreed merger of Vodafone AirTouch and Mannesmann created a telecom giant. The 112-billion-pound all-share deal to acquire Mannesmann turned the merged group into the world's fourth-largest company, worth 224 billion pounds.

Today, 11 years after the dot-com bubble burst, Vodafone is the UK's third-largest company, with a market capitalization of 87 billion pounds. So Vodafone is worth 137 billion pounds (61%) less today than it was before this titanic deal went through. Oops.

2. AOL Time Warner
In another example of disastrous, top-of-the-market folly, U.S. media giant Time Warner (NYSE: TWX  ) announced in January 2000 that it was to team up with then-Internet giant America Online.

Hailed as a visionary "deal of the century," the merger completed a year later, with AOL paying $164 billion in shares for Time Warner and the new entity split 55%/45% in favor of AOL.

AOL and Time Warner parted company in December 2009, after almost nine years of nightmares. In less than a decade, the tie-up had destroyed close to $200 billion of shareholder wealth. 

Today, AOL Time Warner is seen as the poster child for the dot-com madness and is used by business schools to show how not to do a deal.

3. Glaxo Wellcome/SmithKline Beecham
In December 2000, two of the UK's largest pharmaceutical companies, Glaxo Wellcome and SmithKline Beecham, came together to form global giant GlaxoSmithKline  (NYSE: GSK  ) .

At that time, GSK's share price was close to 21 pounds, valuing the firm at close to 110 billion pounds and putting it in the top three of the FTSE 100. Today, more than 10 years on, GSK's share price is around 13 pounds, or 38% lower than at the time of the merger. 

Thus, the GW/SKB tie-up has destroyed roughly 40 billion pounds of shareholder wealth.

4. Prudential/AIA
Lastly, I offer a failed deal -- one that failed to complete yet still caused major headaches for the putative buyer.

In March 2010, UK insurance giant Prudential  (NYSE: PUK  ) launched a breathtaking $35.5 billion bid for AIA, the Asian arm of bailed-out U.S. insurer AIG.

Following regulatory concerns and shareholder revolt, Pru abandoned this deal three months later, having failed to cut the asking price by $5 billion. This left Pru with deal costs nearing 1 billion pounds and CEO Tidjane Thiam with egg all over his face.

What do you think was the worst deal in history? Please tell us in the comments box below!

More from Cliff D'Arcy:

Follow the Fool's coverage of Vodafone, Glaxo, or any other stock by adding them to My Watchlist, our free, personalized stock-tracking service.

The Steve Jobs Betrayal
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Enter your email address below to find out what made Jobs so enraged!

Cliff D'Arcy owns shares of GlaxoSmithKline, as does The Motley Fool. Vodafone Group is a Motley Fool Inside Value pick. GlaxoSmithKline is a Motley Fool Global Gains selection. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 07, 2011, at 11:51 AM, mracz425 wrote:

    Sprint and Nextel. O though I believe Sprint is a good value play today for long-term investors and after the disastrous 2005 merger, Sprint is finally on the road to recovery.

  • Report this Comment On May 08, 2011, at 9:17 AM, TrackTimMaurer wrote:

    Wendy's+Arbys. How about Sears + Kmart? not exactly matches made in heaven, considering WEN now wants to give Arbys the boot.

  • Report this Comment On May 09, 2011, at 9:29 AM, srsmith98 wrote:

    Chiefist surveyed stakeholders of GlaxoSmithKline [GSK] on the leadership of CEO Andrew Witty. Mr. Witty has received significant attention recently, as he seeks to revamp how the pharmaceutical company conducts basic R&D. The crux of the strategy rests on the abandonment of the traditional pharmaceutical industry approach to drug discovery. His plan creates 40 “biotech-like” units, with a mandate to pursue drug discovery autonomously for three years. They will then be held to account for their records.

    Chiefist asked GSK stakeholders to give their thoughts on Mr. Witty’s leadership and ambitions for the company. See more: http://bit.ly/kptYcK

Add your comment.

Compare Brokers

Fool Disclosure

DocumentId: 1490791, ~/Articles/ArticleHandler.aspx, 5/27/2012 6:24:01 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 12,454.83 -74.92 -0.60%
S&P 500 1,317.82 -2.86 -0.22%
NASD 2,837.53 -1.85 -0.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/25/2012 4:00 PM
TWX $34.70 Up +0.12 +0.35%
Time Warner CAPS Rating: ***
PUK $21.32 Down -0.23 -1.07%
Prudential Public… CAPS Rating: **
GSK $44.28 Up +0.04 +0.09%
GlaxoSmithKline CAPS Rating: ****

Advertisement